News & Updates
Showing Multidisciplinary articles
Showing

ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.

Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.

Smartphone app helps control blood sugar in people at risk of T2D
Use of a smartphone application (app) and an intermittently scanned continuous glucose monitoring (isCGM) results in better glycaemic control, lower carbohydrate intake, and weight loss in people at increased risk of type 2 diabetes (T2D), reports a study.





